1. Home
  2. Detail

@coloradoavalanche: Hats marked safe by this much 🤏 #NHL #ColoradoAvalanche #Toews #Makar #Schwartz

Colorado Avalanche
Colorado Avalanche
Open In TikTok:
Region: US
Friday 09 October 2026 22:03:58 GMT
19455
1444
3
14

Music

Download

No Watermark .mp4 (14.36MB) No Watermark(HD) .mp4 (8.42MB) Watermark .mp4 (13.49MB) Music .mp3

Comments

kasebuchanan
Broccoli 🥦 :
First
2026-10-09 22:06:17
2
cherryg1rll
cherryg1rll :
2026-10-09 22:07:07
10
luke___.__.._1
Luke :
what a game for the boys
2026-10-10 00:19:18
0
To see more videos from user @coloradoavalanche, please go to the Tikwm homepage.

Other Videos

Openart is printingg rn #Openart #openart
Openart is printingg rn #Openart #openart
#motivation #merci
#motivation #merci
Quy trình sản xuất xe đạp Thống Nhất #bike #xedapthongnhat #xedap
Quy trình sản xuất xe đạp Thống Nhất #bike #xedapthongnhat #xedap
#Sillenlife #foryoupage
#Sillenlife #foryoupage
GLP-1 research is getting much bigger than weight loss. One of the most interesting conversations I had at EASD was during a private scientific roundtable with Lilly’s leadership and a small group of physicians. We talked about something I think deserves more attention: the gap between what researchers initially set out to study and what clinicians are observing in real-world patient care. Sometimes patients report improvements in symptoms or conditions that weren’t part of the original clinical trials. Those observations can raise important questions, but they still need to be studied before we can say whether the medication is responsible. Now, research is expanding into areas like pain and physical function, psoriatic arthritis, inflammatory bowel disease, and women’s health, including the PERIODS trial investigating tirzepatide in PMOS (formerly PCOS). And one of the biggest unanswered questions is whether potential benefits in these conditions are driven by weight loss, effects of the medication itself, or some combination of both. That distinction matters, especially as we think about which patients might benefit from these treatments in the future. There’s a lot we still don’t know. But these are exactly the kinds of questions I’m glad researchers are beginning to investigate. Research in these areas is ongoing. Investigational uses should not be interpreted as established benefits or approved indications. #GLP1 #GLP1Research #EASD2026 #ObesityMedicine #MetabolicHealth
GLP-1 research is getting much bigger than weight loss. One of the most interesting conversations I had at EASD was during a private scientific roundtable with Lilly’s leadership and a small group of physicians. We talked about something I think deserves more attention: the gap between what researchers initially set out to study and what clinicians are observing in real-world patient care. Sometimes patients report improvements in symptoms or conditions that weren’t part of the original clinical trials. Those observations can raise important questions, but they still need to be studied before we can say whether the medication is responsible. Now, research is expanding into areas like pain and physical function, psoriatic arthritis, inflammatory bowel disease, and women’s health, including the PERIODS trial investigating tirzepatide in PMOS (formerly PCOS). And one of the biggest unanswered questions is whether potential benefits in these conditions are driven by weight loss, effects of the medication itself, or some combination of both. That distinction matters, especially as we think about which patients might benefit from these treatments in the future. There’s a lot we still don’t know. But these are exactly the kinds of questions I’m glad researchers are beginning to investigate. Research in these areas is ongoing. Investigational uses should not be interpreted as established benefits or approved indications. #GLP1 #GLP1Research #EASD2026 #ObesityMedicine #MetabolicHealth


About

Legal